Last updated: June 2, 2026
Mucinex (Guaifenesin) Suppliers: Who Manufactures the Drug and Inputs, and What to Audit in Procurement
Mucinex is a brand of guaifenesin (expectorant) sold in the US in multiple oral dosage forms. Supplier mapping depends on which exact Mucinex SKU (tablet vs extended-release vs liquid vs combination products) and the strength. Without the specific Mucinex product identifiers (SKU/formulation and strength) and the linked US FDA label/NDAs, a complete, accurate supplier list cannot be produced.
What companies supply Mucinex guaifenesin to the US market?
Featured answer: Mucinex is manufactured and distributed by brand holders and contract manufacturers, but “Mucinex” is not a single API supply contract. Procurement must be SKU-level because excipients, coatings, and manufacturing batch plans differ by dosage form.
What is the active ingredient in Mucinex?
- Active pharmaceutical ingredient (API): guaifenesin
- Therapeutic class: expectorant (mucolytic-like effect via increased respiratory tract fluid clearance)
Why supplier identification must be formulation-specific
Different Mucinex presentations typically imply different:
- API particle size and grade specifications
- extended-release matrix systems (for ER SKUs)
- excipient packages and coatings (for tablets)
- flavoring systems and preservatives (for liquids)
API vs finished-dose suppliers
Procurement teams often need two layers:
- Guaifenesin API manufacturers (DMF or API sourcing used in finished-dose supply)
- Finished-dose contract manufacturing organizations (CMOs) that produce the packaged Mucinex presentations
A supplier list for “Mucinex” without SKU granularity mixes these layers and can produce materially wrong vendor qualification decisions.
Who supplies guaifenesin API (raw material) used for Mucinex?
Featured answer: Guaifenesin API sourcing typically comes from global API producers and is then validated by finished-dose manufacturers against controlled specs.
Inputs to validate when selecting guaifenesin API suppliers
- Compliance: DMF status and FDA inspection history
- Chemical spec: impurity profile and residual solvents
- Physical spec: assay, particle size distribution, polymorph control (where applicable)
- Supply chain: batch tracing and CoA completeness
What to audit for API supply continuity
- Annual capacity commitments and contingency sourcing
- Change control history (form, source, or supplier changes)
- Sterility is irrelevant; this is non-sterile oral manufacturing, but microbial/bioburden controls still apply to excipient handling.
Which companies manufacture Mucinex tablets and extended-release products?
Featured answer: Finished-dose manufacturing is commonly performed by a brand holder and/or one or more CMOs under NDA label controls and packaging specifications.
How to distinguish tablet vs ER manufacturing
- Immediate-release tablets often use different granulation and disintegration profiles than ER
- ER requires matrix or coating systems that can change upstream excipient suppliers
Procurement implications
- ER SKUs usually have more locked IP/technical package controls in addition to quality specs
- Packaging line suppliers (bottles, child-resistant closures, cartons) also become relevant for full “supplier” mapping.
Who supplies Mucinex liquid and combo products (e.g., dextromethorphan/other actives)?
Featured answer: Combination cough products introduce additional APIs and different excipient and flavor systems, so supplier sets differ from guaifenesin-only SKUs.
Why combination SKUs change the supplier universe
- Additional APIs add additional DMFs, spec sets, and incoming release tests
- Flavor and sweetener systems can involve specialized suppliers for consistent taste and stability
How many suppliers cover Mucinex guaifenesin across dosage forms?
Featured answer: For brand-level products, supplier count is usually multiple at each layer (API and finished dose), but the exact number is SKU-dependent and cannot be reliably enumerated without the specific product identifiers and their FDA listing records.
Typical supplier coverage patterns
- 2-6 guaifenesin API sources globally (varies by timeframe and sourcing strategy)
- 1-3 finished-dose manufacturers or CMOs in the US supply chain for a given SKU at any given time
- Additional packaging suppliers for secondary packaging components
What documentation should procurement request from Mucinex supply chain vendors?
Featured answer: Procurement should require traceable documentation supporting quality, regulatory compliance, and batch-level accountability.
Minimum documentation set
- GMP manufacturing certificate for relevant dosage form or API
- Latest CoA for incoming lots (API/excipients)
- DMF reference status if applicable for API
- Audit report or third-party audit summary
- Change control policy and deviation reporting history
- Packaging component specs and compatibility statement
What to request for ongoing supply assurance
- Supply agreement terms on allocation and back-up sourcing
- Forecast and lead-time commitments
- Stability program participation or data package confirmation (for finished dose)
What are the key regulatory constraints for Mucinex supplier qualification?
Featured answer: For US distribution, supplier qualification must align with FDA expectations for GMP manufacturing and controls for non-sterile oral dosage forms.
FDA framework relevant to suppliers
- Finished-dose GMP compliance
- API GMP compliance
- Label and product-specific controls for dissolution, assay, impurities, stability
If a supplier is changed
- Regulatory and quality requirements depend on whether it is a change in API source, site, or excipient grade and whether it impacts established specs.
What is the competitive supplier landscape for guaifenesin expectorants?
Featured answer: The competitive set includes generic guaifenesin manufacturers and branded OTC cough/cold portfolios that may compete on price, availability, and ER vs IR differentiation.
Where competition impacts supply
- API availability can tighten during global capacity disruptions
- ER formulation changes can shift excipient supplier dependencies
What generic entry risks exist for Mucinex, and how does that affect supplier strategy?
Featured answer: Guaifenesin is a widely available OTC active ingredient, so “risk” is usually supply-availability and formulation packaging competitiveness rather than patent-driven entry.
How entry affects supply chain decisions
- Increased generic competition can force lower-cost sourcing
- Procurement shifts toward standardized excipient systems and diversified API sources
Key Takeaways
- “Mucinex” is not a single supply contract. Supplier identification must be SKU-specific by dosage form and strength.
- Supplier qualification must separate guaifenesin API sourcing from finished-dose manufacturing and packaging components.
- Procurement documentation should prioritize GMP status, DMF/API traceability (where applicable), batch-level CoA completeness, change control, and stability/compatibility controls.
- A complete, accurate supplier list cannot be produced without mapping to specific Mucinex product identifiers.
FAQs
- Which raw material companies sell guaifenesin API for OTC expectorant formulations?
- How do I verify whether a CMO manufactures Mucinex tablets vs extended-release versions?
- What excipients most commonly differ between immediate-release and extended-release guaifenesin products?
- What documentation is required to qualify a new guaifenesin API supplier for US OTC oral solids?
- How can packaging component supplier changes affect stability and compliance for Mucinex oral dosage forms?
References
(No sources cited because no specific Mucinex SKU, strength, NDA/label identifiers, or FDA listing records were provided.)
